Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been given an average recommendation of “Reduce” by the eight analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $24.00.

A number of research firms have issued reports on IART. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. JMP Securities reduced their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Bank of America dropped their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Finally, Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th.

Institutional Trading of Integra LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp grew its stake in Integra LifeSciences by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock worth $2,110,000 after acquiring an additional 870 shares in the last quarter. Concurrent Investment Advisors LLC increased its stake in shares of Integra LifeSciences by 17.3% during the first quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company’s stock valued at $601,000 after buying an additional 2,500 shares during the period. Inspire Investing LLC raised its holdings in shares of Integra LifeSciences by 14.8% in the first quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company’s stock valued at $360,000 after acquiring an additional 1,311 shares in the last quarter. Headlands Technologies LLC lifted its stake in Integra LifeSciences by 54.3% in the first quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company’s stock worth $169,000 after acquiring an additional 1,677 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Integra LifeSciences by 8.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,502 shares of the life sciences company’s stock worth $1,790,000 after acquiring an additional 3,743 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Down 1.7 %

NASDAQ IART opened at $22.49 on Tuesday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The stock’s 50 day moving average is $19.64 and its 200 day moving average is $24.09. The stock has a market cap of $1.74 billion, a PE ratio of -249.86, a P/E/G ratio of 0.78 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.76 earnings per share. Research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.